{
    "nct_id": "NCT03300570",
    "official_title": "Phase I Double-Blind, Placebo-Controlled Trial of 27 mg Dolcanatide (SP-333) to Demonstrate Colorectal Bioactivity in Healthy Volunteers",
    "inclusion_criteria": "* PRE-REGISTRATION INCLUSION\n* Able to understand and willingness to sign a written informed consent document and follow study procedures\n* Willing to abstain from grapefruit juice during study\n* Willing to employ adequate contraception for men and women of childbearing potential; Note: acceptable methods include double barrier methods, intrauterine device (IUD), postmenopausal status documented by serum follicle stimulating hormone (FSH), and/or documentation of surgical sterilization\n* Willing to provide blood and tissue specimens for research purposes\n* REGISTRATION INCLUSION\n* Normal organ function and have normal laboratory findings without clinically significant findings\n* Leukocytes >= 3 x 10^3/microliter (B/L)\n* Absolute neutrophil count >= 1.5 x 10^3/microliter (B/L)\n* Platelets >= 100 x 10^3/microliter (B/L)\n* Total bilirubin within normal institutional limits\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional upper limit of normal (ULN)\n* Creatinine =< institutional upper limit of normal\n* Body mass index < 35 kg/m^2\n* No findings in the rectum of advanced adenoma, chronic inflammation, or cancer\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* PRE-REGISTRATION EXCLUSION\n* Documented history of advanced adenomas (>= 1 cm in maximal diameter, >= 3 in total number, villous morphology, or high-grade dysplasia) or colorectal cancer\n* Family history of polyposis syndrome (e.g., familial adenomatous polyposis [FAP], hereditary nonpolyposis colorectal cancer [HNPCC]) or colorectal cancer (first degree relatives younger than 60 years old)\n* History of gastroparesis\n* History of surgery involving the luminal gastrointestinal (GI) tract, including bariatric surgery; exception: prior appendectomy >= 60 days prior to pre-registration is not an exclusion criterion\n* History of celiac disease\n* Inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n* Previous diagnosis of irritable bowel syndrome, chronic constipation, functional bowel disorders, colonic motility disorder, or opioid-induced constipation\n* Any malignancy within 3 years of baseline; exception: participants with a history of basal cell or squamous cell skin cancer may be enrolled at the discretion of the investigator\n* Currently receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to dolcanatide or to any of the excipients\n* History of difficulty with sigmoidoscopy or abnormal colorectal anatomy\n* Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant or lactating women\n* Current use of laxatives more than 3 times per week\n* Current use of >= 5 cigarettes/day\n* Current use of >= 3 alcoholic drinks/day\n* Use of anti-coagulants or anti-platelet agents within 5 days prior to anticipated sigmoidoscopy; exception: individuals taking aspirin will not be excluded and will not be subject to a wash-out period\n* History of bleeding/coagulation problems\n* Any medical condition reported by the participant or documented in the medical record that is judged by the investigator to constitute a risk to safe participation\n* Known or suspected mechanical gastrointestinal obstruction\n* REGISTRATION EXCLUSION\n* Sigmoidoscopy finding requiring clinical intervention\n* Use of any illicit or illegal substances detected by urinary drug screen",
    "miscellaneous_criteria": ""
}